Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter

被引：0
作者：
Sonal Gandhi
Sunil Verma
机构：
[1] University of Toronto,
[2] Toronto Sunnybrook Regional Cancer Centre,undefined
来源：
Breast Cancer Research and Treatment | 2007年 / 106卷
关键词：
Adjuvant therapy; Aromatase inhibitors; Breast cancer; Cardiovascular events; Lipids; Tamoxifen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent advances in breast cancer treatment include the advent of aromatase inhibitors (AIs) in the adjuvant setting with better efficacy and toxicity profiles than tamoxifen. However, AIs generally do not improve lipid profile as tamoxifen does, and there has been suggestion of increased cardiovascular risk with AI use. This has become an area of concern, particularly in light of the view that tamoxifen may protect against cardiovascular disease. This review of the current literature and updated trial data examines the effect both AIs and tamoxifen have on lipids and cardiovascular risk. It also highlights the importance of interpreting such data within the larger context of cardiovascular health in postmenopausal women.
引用
收藏
页码：1 / 9
页数：8
相关论文
共 111 条
  • [1] Clemons M(2004)Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 30 325-332
  • [2] Coleman RE(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer NEJM 355 2747-2757
  • [3] Verma S(2003)Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer Cancer 98 1802-1810
  • [4] Coombes RC(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer NEJM 350 1081-1092
  • [5] Hall E(2005)Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of the ABCSG trial 8 and ARNO 95 trial Lancet 366 455-462
  • [6] Gibson LJ(2006)Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: updated results of the Italian tamoxifen anastrozole (ITA) trial Ann Oncol 17 vii10-vii14
  • [7] Jakesz R(2003)A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer NEJM 349 1793-1802
  • [8] Jonat W(2006)Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the preoperative “Arimidex” compared to Tamoxifen (PROACT) trial Cancer 106 2095-2103
  • [9] Gnant M(1995)The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women J Clin Endocrinol Metab 80 3191-3195
  • [10] Boccardo F(2006)Cardiovascular safety profiles of aromatase inhibitors: a comparative review Drug Saf 29 785-801
12345678910